Safety issue puts daclizumab in doubt for MS

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Safety issue puts daclizumab in doubt for MS

Postby MSUK » Mon Oct 15, 2012 1:08 pm


Daclizumab, a biologic drug targeting the interleukin-2 pathway, showed sustained efficacy in the second year of a phase II trial in multiple sclerosis, but serious autoimmune issues also emerged, researchers said here.

In a randomized extension study of high-yield process daclizumab called SELECTION, efficacy according to most measures was maintained or even increased in relapsing-remitting MS patients who had participated in the one-year SELECT trial, according to Gavin Giovannoni, MD, of Queen Mary University in London.

But one patient died from autoimmune hepatitis and two others developed autoimmune conditions affecting vital organs, he reported at a late-breaking abstract session at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis.

Hepatic monitoring in the daclizumab clinical program was stepped up after the potential for such effects was recognized, Giovannoni said. Nevertheless, other researchers suggested that the problem was serious enough to jeopardize the drug's future in MS.... Read More - ... ageid/1502
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Re: Safety issue puts daclizumab in doubt for MS

Postby jimmylegs » Wed Oct 17, 2012 5:21 pm

link to abstract

Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis ... KEN_ID=900
odd sx? no dx? check w/ dietitian
99% don't meet these. meds/lifestyle can affect levels
status can be low in ms & other cond'ns
'but my results are normal'. typical panels don't test all
deficits occur in 'normal' range
User avatar
Volunteer Moderator
Posts: 11119
Joined: Sat Mar 11, 2006 4:00 pm

Return to General Discussion


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service